4-[3-(1-Methylethyl)-5-(6-phenyl-3-pyridinyl)-4H-1,2,4-triazol-4-yl]-2,1,3-benzoxadiazole
ASP2535
CAS: 374886-51-8
Molecular Formula: C22H18N6O
4-[3-(1-Methylethyl)-5-(6-phenyl-3-pyridinyl)-4H-1,2,4-triazol-4-yl]-2,1,3-benzoxadiazole - Names and Identifiers
| Name | ASP2535 |
| Synonyms | ASP2535 ASP 2535 4-[3-(1-Methylethyl)-5-(6-phenyl-3-pyridinyl)-4H-1,2,4-triazol-4-yl]-2,1,3-benzoxadiazole |
| CAS | 374886-51-8 |
4-[3-(1-Methylethyl)-5-(6-phenyl-3-pyridinyl)-4H-1,2,4-triazol-4-yl]-2,1,3-benzoxadiazole - Physico-chemical Properties
| Molecular Formula | C22H18N6O |
| Molar Mass | 382.42 |
| Appearance | Solid |
| Storage Condition | 2-8°C，密封，干燥 |
| In vitro study | ASP2535 potently inhibits rat GlyT1 (IC 50 =92 nM) with 50-fold selectivity over rat glycine transporter-2 (GlyT2) in vitro. |
4-[3-(1-Methylethyl)-5-(6-phenyl-3-pyridinyl)-4H-1,2,4-triazol-4-yl]-2,1,3-benzoxadiazole - Reference Information
| biological activity | ASP-2535 is a highly effective, glit1 inhibitors of brain permeability and central activity. ASP-2535 improved Cognitive Disorder in animal models of schizophrenia and Alzheimer's disease. |
| Target | GlyT1 |
| Animal Model: | 5-week-old male ddY mice |
| Dosage: | 0.1 mg/kg, 0.3 mg/kg, 1 mg/kg, 3 mg/kg |
| Administration: | Oral administration |
| Result: | Significantly attenuated the MK-801-induced decrease in alternation rate. |
Last Update：2024-04-09 21:11:58
![4-[3-(1-Methylethyl)-5-(6-phenyl-3-pyridinyl)-4H-1,2,4-triazol-4-yl]-2,1,3-benzoxadiazole](http://res.chembk.com/assets/str/2d/3/37/374886-51-8.png)
Supplier List
View History